Currently under development, the CapioCyte platform utilizes proprietary chips that are inserted into a specially designed flow chamber. Samples are then passed through this flow chamber at a precisely controlled rate. The surface of the chip is specially treated to induce biomimetic cell rolling to enable cell capture utilizing antibodies bound to dendrimers. Once captured, CTCs can either be recovered for post capture analysis such as RNA-Seq, or they can be automatically stained for subsequent fluorescence image capture, enumeration and analysis. Ultimately, the CapioCyte Platform will have the flexibility to use different capture antibodies for different target cell populations. CapioCyte technology may help researchers further understand the role of CTCs, identify specific patient subpopulations for drug trials, and help in the development of new cancer drugs. In addition, CapioCyte may have an important role for clinical patient management in the future.